

## Colorectal Cancer: Pathway to Survival

### REFERENCES

- Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg*. 2004;240:644-657.
- Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. *J Clin Oncol*. 2008;26(suppl):179s. Abstract 4006.
- American Cancer Society. Cancer facts & figures 2005. [http://www.cancer.org/docroot/STT/stt\\_0\\_2005.asp?sitearea=STT&level=1](http://www.cancer.org/docroot/STT/stt_0_2005.asp?sitearea=STT&level=1).
- American Cancer Society. Cancer facts & figures 2007. [http://www.cancer.org/docroot/STT/content/STT\\_1x\\_Cancer\\_Facts\\_Figures\\_2007.asp](http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_Figures_2007.asp).
- American Cancer Society. Colorectal cancer facts and figures: special edition 2005. [http://www.cancer.org/docroot/STT/stt\\_0\\_2005.asp?sitearea=STT&level=1](http://www.cancer.org/docroot/STT/stt_0_2005.asp?sitearea=STT&level=1).
- American Cancer Society. Guidelines for the early detection of cancer 2007. [http://www.cancer.org/docroot/PED/content/PED\\_2\\_3X\\_ACS\\_Cancer\\_Detection\\_Guidelines\\_36.asp?sitearea=PED](http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp?sitearea=PED).
- Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. *Clin Pharmacol Ther*. 2005;78:559-581.
- Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. *Neurology*. 2005;64:26-31.
- Arkenau H, Englisch-Fritz C, Kubicka S, et al. Oxaliplatin in combination with capecitabine or 5-fluorouracil/leucovorin in elderly patients (>70 yrs) with metastatic colorectal cancer (MCRC). 2007 ASCO Gastrointestinal Cancers Symposium. Abstract 283. <http://www.asco.org>.
- Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy [review]. *Oncol Nurs Forum*. 2005;32:305-311.
- Avastin (bevacizumab) prescribing information (2006). <http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf>.
- Balducci L, Yates J. General guidelines for the management of older patients with cancer. *Oncology (Williston Park)*. 2000;14:221-227.
- Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med*. 2003;348:891-899.
- Barrier A, Boelle P-Y, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. *J Clin Oncol*. 2006;24:4685-4691.
- Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. *J Clin Oncol*. 2004;22:2918-2926.
- Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol*. 2004;22:3408-3419.
- Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. *J Clin Oncol*. 2005;23:8706-8712.
- Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. *J Clin Oncol*. 2007;25(suppl):196s. Abstract 4134.
- Berry SR, Van Cutsem E, Kretschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. *J Clin Oncol*. 2008;26(suppl):184s. Abstract 4025.
- Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J Clin Oncol*. 1999;17:485-493.
- Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. *J Clin Oncol*. 2008;26(suppl):178s. Abstract 4000.
- Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. *J Clin Oncol*. 2007;25(suppl):172s. Abstract 4035.
- Cai Q, Sullivan PA, Yeh Y, Russell M. Assessing 12 or more lymph nodes increases the proportion of stage III disease in colorectal cancer (CRC): evidence from the Surveillance, Epidemiology and End Results (SEER) cancer registry. *J Clin Oncol*. 2007;25(suppl):167s. Abstract 4016.
- Camptosar (irinotecan HCl injection) prescribing information (2006). [http://www.pfizer.com/pfizer/download/uspi\\_camptosar.pdf](http://www.pfizer.com/pfizer/download/uspi_camptosar.pdf).
- Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J Clin Oncol*. 2002;20:3478-3483.
- Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). 2006 ASCO Gastrointestinal Cancers Symposium. Abstract 229. <http://www.asco.org>.

## Colorectal Cancer: Pathway to Survival

### REFERENCES (CONT)

- Centers for Disease Control and Prevention (CDC). National Comprehensive Cancer Control Program (NCCCP). <http://www.cdc.gov/cancer/ncccp/>.
- Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg*. 2002;235:759-766.
- Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*. 2004;350:2050-2059.
- Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. *Cancer Causes Control*. 2000;11:477-488.
- de Gramont A, Boni C, Navarro C, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized MOSAIC trial. *Proc Am Soc Clin Oncol*. 2003;22:253. Abstract 1015.
- Demark-Wahnefried W. Cancer survival: time to get moving? Data accumulate suggesting a link between physical activity and cancer survival. *J Clin Oncol*. 2006;24:3517-3518.
- Dick SE, Crawford GH. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. *Community Oncol*. 2005;2:492-496.
- Eckford JF, Gonzalez MV, Ashley P, et al. Stage II colon cancer and chemotherapy: sixteen year experience at a single institution. 2006 Gastrointestinal Cancers Symposium. Abstract 366. <http://www.asco.org>.
- Eloxatin (oxaliplatin for injection) prescribing information (2006). <http://www.eloxatin.com>.
- Erbix (cetuximab) prescribing information (2007). <http://www.erbitux.com>.
- Falci C, Pasetto LM, Basso U, Monfardini S. A phase II study of an adapted CT with oxaliplatin (Oxa) and bolus 5FU in 1-line treatment of metastatic CRC in elderly patients not eligible to FOLFOX. *J Clin Oncol*. 2008;26(suppl):654s. Abstract 15124.
- Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg*. 2004;240:438-447.
- Folprecht G, Rougier P, Saltz L, et al. Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: meta-analysis of four trials investigating 5-FU and irinotecan. *J Clin Oncol*. 2006;24(suppl):165s. Abstract 3578.
- Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. *J Clin Oncol*. 2007;25(suppl):181s. Abstract 4071.
- Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver [review]. *CA Cancer J Clin*. 1995;45:50-62.
- Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg*. 1999;230:309-318.
- Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. *Clin Cancer Res*. 2004;10:4055-4061.
- Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. *Surgery*. 1994;116:703-710.
- Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. *J Clin Oncol*. 2005;23(suppl):1s. Abstract 2.
- Goetz MP, Ames MM, Weinshilboum RM. Primer on medical genomics. Part XII: Pharmacogenomics—general principles with cancer as a model. *Mayo Clin Proc*. 2004;79:376-384.
- Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol*. 2004;22:23-30.
- Greene FL, Page DL, Fleming ID, et al, eds. *AJCC Cancer Staging Manual*. 6th ed. New York, NY: Springer; 2002.
- Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine [review]. *J Oncol Pharm Pract*. 2006;12:131-41.
- Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcept trial. *J Clin Oncol*. 2008;26(suppl):180s. Abstract 4010.
- Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. *J Clin Oncol*. 2004;22:1209-1214.
- Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). *J Clin Oncol*. 2007;25(suppl):172s. Abstract 4036.
- Gruenberger B, Scheithauer W, Tamandi D, et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases. *J Clin Oncol*. 2007;25(suppl):178s. Abstract 4060.

## Colorectal Cancer: Pathway to Survival

### REFERENCES (CONT)

- Gruenberger BT, Tamandi D, Puhalla H, et al. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. *J Clin Oncol*. 2007;25(suppl):179s. Abstract 4064.
- Health politics with Dr Mike Magee. [http://www.healthpolitics.com/media/colorectal\\_cancer/slides\\_colorectal\\_cancer.pdf](http://www.healthpolitics.com/media/colorectal_cancer/slides_colorectal_cancer.pdf). Accessed October 26, 2007.
- Hochster et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. *J Clin Oncol*. 2007;25:4028-4029.
- Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. *Surgery*. 1986;100:278-284.
- Imperiale TF. Aspirin and the prevention of colorectal cancer. *N Engl J Med*. 2003;348:879-880.
- Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol*. 2004;22:1382-1388.
- Iyer L, Das S, Janisch L, et al. UGT1A1\*28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J*. 2002;2:43-47.
- Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. *Arch Surg*. 1997;132:505-510.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin*. 2008;58:71-96.
- Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. *Am Surg*. 1997;63:605-610.
- Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol*. 2005;23:3706-3712.
- Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. *Ann Oncol*. 2005;16:869-877.
- Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. *J Clin Oncol*. 2007;25(suppl):171s. Abstract 4033.
- Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. *J Clin Oncol*. 2008;26(suppl):184s. Abstract 4026.
- KRAS slide set. KRAS information. [http://www.kras-info.com/slide\\_set](http://www.kras-info.com/slide_set). Accessed August 12, 2008.
- Kretzschmar A, Van Cutsem E, Michael M, et al. Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: first BEATrial. *J Clin Oncol*. 2007;25(suppl):181s. Abstract 4072.
- Lacouture ME, Walker S. Skin-related toxicities of targeted therapies [wall chart included with issue]. *Oncology*. 2006;20(10 suppl 7).
- Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). *Eur J Oncol Nurs*. 2004;8(suppl 1):S31-S40.
- Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. *Oncologist*. 2005;10:104-111.
- Leichman L. Neoadjuvant chemotherapy for disseminated colorectal cancer: changing the paradigm. *J Clin Oncol*. 2006;24:3817-3818.
- Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. *Oncologist*. 2007;12:601-609.
- Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin*. 2008;58:130-160.
- Lichtman SM. Guidelines for the treatment of elderly cancer patients [review]. *Cancer Control*. 2003;10:445-453.
- Love N, Bylund C, Meropol NJ, et al. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. *J Clin Oncol*. 2007;25(suppl):168s. Abstract 4020.
- Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. *Oncologist*. 2007;12:610-621.
- Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. *J Clin Oncol*. 2007;25(suppl):166s. Abstract 4013.
- Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. *Clin Colorectal Cancer*. 2001;3:175-178.
- McDonald SA, Preston SL, Lovell MJ, et al. Mechanisms of disease: from stem cells to colorectal cancer [review]. *Nat Clin Pract Gastroenterol Hepatol*. 2006;3:267-274.

## Colorectal Cancer: Pathway to Survival

### REFERENCES (CONT)

Medical University of South Carolina Digestive Disease Center Public Information site. Digestive problems: colon & rectum—colorectal cancer. <http://www.ddc.musc.edu>.

Meyerhardt JA. Post-colorectal cancer treatment: what else can I do? *Clin Rev*. July/August 2007;1-4.

Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. *J Clin Oncol*. 2006;24:3527-3534.

Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *J Clin Oncol*. 2006;24:3535-3541.

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. *N Engl J Med*. 2005;352:476-487.

Mullan F. Seasons of survival: reflections of a physician with cancer. *N Engl J Med*. 1985;313:270-273.

National Cancer Institute. Colon cancer treatment: stages of colon cancer. <http://www.cancer.gov/cancertopics/pdq/treatment/colon/Patient/page2>.

National Cancer Institute. Common Toxicity Criteria v.2. [http://ctep.cancer.gov/reporting/ctc\\_archive.html](http://ctep.cancer.gov/reporting/ctc_archive.html).

NCCN Clinical Practice Guidelines in Oncology: Colon Cancer—v.1.2008. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).

NCCN Clinical Practice Guidelines in Oncology: Senior Adult Oncology—v.2.2007. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).

Nikcevich DA, Grothey A, Sloan JA, et al. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. *J Clin Oncol*. 2008;26(suppl):180s. Abstract 4009.

Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. *J Clin Oncol*. 2007;25(suppl):2s. Abstract LBA5.

O'Keefe P, Parilli M, Lacouture ME. Toxicity of targeted therapy: focus on rash and other dermatologic side effects. *Oncology*. 2006;20(13 suppl 12):25-30.

O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. *J Clin Oncol*. 2007;25:3644-3648.

Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. *J Natl Cancer Inst*. 2002;94:652-661.

Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. *Ann Surg*. 2005;241:715-722.

Peeters M, Van Cutsem E, Berlin J, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. *J Clin Oncol*. 2007;25(suppl):197s. Abstract 4138.

Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. Presented at: the 97th Annual Meeting of the American Association for Cancer Research; April 1-5, 2006; Washington, DC. Abstract CP-1.

Peeters M, Wilson G, Ducreux M, et al. Phase III study (20050181) of panitumumab(p Mab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results. *J Clin Oncol*. 2008;26(suppl):194s. Abstract 4064.

Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. *Oncologist*. 2005;10:345-356.

Pullarkat S, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. *Pharmacogenomics J*. 2001;1:65-70.

Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. *J Clin Oncol*. 2002;20:4303-4312.

Ruers T, van Coevorden F, Pierie J, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). *J Clin Oncol*. 2008;26(suppl):181s. Abstract 4012.

Saltz LB. Understanding and managing chemotherapy-induced diarrhea. *J Support Oncol*. 2003;1:35-46.

Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. *J Clin Oncol*. 2007;25(suppl):170s. Abstract 4028.

Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). *J Clin Oncol*. 2004;22(suppl 14):245s. Abstract 3500.

## Colorectal Cancer: Pathway to Survival

### REFERENCES (CONT)

- Samad AK, Taylor RS, Marshall T, Chapman MA. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. *Colorectal Dis*. 2005;7:204-213.
- Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med*. 2003;348:883-890.
- Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. *N Engl J Med*. 2001;345:1091-1097.
- Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. *J Clin Oncol*. 2008;26(suppl):180s. Abstract 4008.
- Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. *Eur J Cancer*. 2005;41:272-279.
- Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I [review]. *Cancer J*. 2005;11:449-460.
- Scheele J, Altendorf-Hofmann A, Grube T, et al. Resection of colorectal liver metastases. What prognostic factors determine patient selection [German]? *Chirurg*. 2001;72:547-560.
- Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. *World J Surg*. 1995;19:59-71.
- Schrag D. *N Engl J Med*. The price tag on progress—chemotherapy for colorectal cancer. 2004;351:317-319.
- Siena S, Taberero J, Burkes RL, et al. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. *J Clin Oncol*. 2008;26(suppl):186s. Abstract 4034.
- Simoni JM, Frick PA, Pantalone DW, et al. Antiretroviral adherence interventions: a review of current literature and ongoing studies. *Top HIV Med*. 2003;11:185-198.
- Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. *CA Cancer J Clin*. 2007;57:90-104.
- Tejpar S, Peeters M, Humblet Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data. *J Clin Oncol*. 2006;24(suppl):159s. Abstract 3554.
- Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w): the EVEREST experience (preliminary data). *J Clin Oncol*. 2008;26(suppl):178s. Abstract 4001.
- Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*. 2004;22:229-237.
- Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: a GERCOR study. *J Clin Oncol*. 2006;24:394-400.
- Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med*. 2005;352:2696-2704.
- US Preventive Services Task Force Recommendations and Rationale (USPSTF, July 2002). <http://www.ahrq.gov/clinic/3rduspstf/colorectal/colorr.htm>. Accessed October 26, 2007.
- Vallböhmer D, Yang DY, Kuramochi H, et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. *Int J Oncol*. 2007;31:413-418.
- Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. ASCO 2007 Gastrointestinal Cancers Symposium. <http://www.asco.org>. Abstract 237.
- Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase II trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid versus 5-FU/FA in stage III colon cancer patients (PETACC 3). *J Clin Oncol*. 2005;23(suppl 16):3s. Abstract LBA8.
- Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with or without cetuximab: the CRYSTAL experience. *J Clin Oncol*. 2008;26(suppl):5s. Abstract 2.
- Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. *J Clin Oncol*. 2007;25(suppl):164s. Abstract 4000.
- Venook A. Critical evaluation of current treatments in metastatic colorectal cancer [review]. *Oncologist*. 2005;10:250-261.
- Viale et al. Advanced colorectal cancer: current treatment and nursing management with economic considerations. *Clin J Oncol Nurs*. 2005;9:541-552.

## Colorectal Cancer: Pathway to Survival

Walgren RA, Meucci MA, McLeod HL, et al. Pharmacogenomic discovery approaches: will the real genes please stand up? *J Clin Oncol*. 2005;23:7342-7349.

Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice [review]. *Clin J Oncol Nurs*. 2007;11:361-376.

Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. *Clin J Oncol Nurs*. 2005;9:31-44.

Winstead ER. Master protein controls multiple myeloma cells. *NCI Cancer Bulletin*. June 24, 2008;13(5):1. [http://www.cancer.gov/NCICancerBulletin/NCI\\_Cancer\\_Bulletin\\_062408](http://www.cancer.gov/NCICancerBulletin/NCI_Cancer_Bulletin_062408).

Wolmark N, Wieand S, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III

carcinoma of the colon: results of NSABP Protocol C-07. *J Clin Oncol*. 2005;24(suppl):246s. Abstract LBA3500.

Wolmark N, Wieand S, Kuebler PJ, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. *J Clin Oncol*. 2008;26(suppl):179s. Abstract LBA4005.

Xeloda (capecitabine tablets) prescribing information. Cancer chemotherapy and hand-foot syndrome: guidelines for coping with skin problems during cancer chemotherapy. <http://www.xeloda.com/pdf/xeloda-hand-foot-syndrome.pdf>. 2006.

Zuckerman IH, Davidoff AJ, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis. *J Clin Oncol*. 2008;26(suppl):181s. Abstract 4014.